64965-47-5 Usage
General Description
3-Bromo-4-hydroxyquinoline is a chemical compound with the molecular formula C9H6BrNO. It is a brominated derivative of 4-hydroxyquinoline and is used as a reagent in organic synthesis and pharmaceutical research. It is a yellow to brown solid at room temperature and is soluble in organic solvents such as ethanol and acetone. 3-BROMO-4-HYDROXYQUINOLINE is known for its antimicrobial and antifungal properties, and it is also used in the production of agrochemicals and pharmaceuticals. 3-Bromo-4-hydroxyquinoline is an important building block for the synthesis of various biologically active compounds and has potential applications in the field of medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 64965-47-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,4,9,6 and 5 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 64965-47:
(7*6)+(6*4)+(5*9)+(4*6)+(3*5)+(2*4)+(1*7)=165
165 % 10 = 5
So 64965-47-5 is a valid CAS Registry Number.
InChI:InChI=1/C9H6BrNO/c10-7-5-11-8-4-2-1-3-6(8)9(7)12/h1-5H,(H,11,12)
64965-47-5Relevant articles and documents
Catalytic atroposelective dynamic kinetic resolutions and kinetic resolutions towards 3-arylquinolinesviaSNAr
Cardenas, Mariel M.,Saputra, Mirza A.,Gordon, Deane A.,Sanchez, Andrea N.,Yamamoto, Nobuyuki,Gustafson, Jeffrey L.
supporting information, p. 10087 - 10090 (2021/10/06)
Herein we report the catalytic atroposelective syntheses of pharmaceutically relevant 3-arylquinolinesviathe nucleophilic aromatic substitution (SNAr) of thiophenols into 3-aryl-2-fluoroquinolines mediated by catalytic amounts of Cinchona alkaloid-derived ureas. These reactions displayed a spectrum of dynamic kinetic resolution (DKR) and kinetic resolution (KR) characters depending upon the stereochemical stability of the starting material. Low barrier substrates proceededviaDKR while higher barrier substrates proceededviaKR. On the other hand, substrates with intermediate stabilities displayed hallmarks of both DKR and KR. Finally, we also show that we can functionalize the atropisomerically enriched quinolines into pharmaceutically privileged scaffolds with minimal observed racemization.